达格列净在射血分数保留型心力衰竭合并阵发性心房颤动患者中的预后分析

李季; 史斌浩; 郝艳成; 王建飞

doi:10.13201/j.issn.1001-1439.2024.07.013

达格列净在射血分数保留型心力衰竭合并阵发性心房颤动患者中的预后分析

- 1.
  蚌埠医科大学研究生院(安徽蚌埠，233030)
- 2.
  安徽省第二人民医院心血管内科
基金项目:
2021年度安徽省高校自然科学研究一般项目(No：ZR2021B003)；职业健康安徽省重点实验室2024年度开放课题一般项目(No：2024ZYJKC005)

详细信息

通讯作者: 王建飞，E-mail：liji0117@outlook.com

中图分类号: R541.6

收稿日期: 2024-02-24

刊出日期: 2024-07-13

Prognostic of dapagliflozin in patients with ejection fraction preserving heart failure combined with paroxysmal atrial fibrillation

- 1.
  Graduate School of Bengbu Medical University, Bengbu, Anhui, 233030, China
- 2.
  Department of Cardiology, Anhui No.2 Provincial People's Hospital

More Information

Corresponding author: WANG Jianfei, E-mail: liji0117@outlook.com

Received Date: 24 February 2024

Publish Date: 13 July 2024

摘要

摘要: 目的探讨达格列净治疗射血分数保留型心力衰竭(HFpEF)合并阵发性心房颤动(PAF)的临床疗效。方法选取2023年1月-2023年4月安徽省第二人民医院200例HFpEF合并PAF患者, 采用随机数字表法将患者分为试验组和对照组各100例。对照组予常规药物治疗, 试验组予常规药物联合达格列净治疗。观察两组治疗前及治疗后3、6、9个月心房颤动(房颤)每月发作次数、每次房颤最长持续时间、血浆N末端B型利钠肽前体(NT-proBNP)、白细胞介素-6(IL-6)、左心室质量分数(LVMI)、左心房容积指数(LAVI)、24 h平均心室率、QTc间期等指标, 以及治疗期间不良反应、治疗9个月后因心力衰竭再住院情况。结果对照组和试验组治疗后3、6、9个月房颤每月发作次数、每次房颤最长持续时间、NT-proBNP、IL-6、LVMI、LAVI、24 h平均心室率、QTc间期均显著改善, 且改善程度随着治疗时间的延长而增强, 同时试验组改善幅度较对照组显著(均P < 0.05)。治疗9个月后, 试验组心力衰竭再住院率低于对照组(38% vs 25%, χ²=3.916, P=0.048)。治疗期间, 两组不良反应发生率差异无统计学意义(9% vs 7%, χ²=0.270, P=0.603)。结论达格列净可改善HFpEF合并PAF患者心脏功能, 缓解心房及心室重构, 提高远期预后, 具有良好的安全性。
- 达格列净 /
- 射血分数保留型心力衰竭 /
- 阵发性心房颤动 /
- 心脏功能
Abstract: Objective To investigate the clinical efficacy of dapagliflozin in the treatment of ejection fraction preserving heart failure (HFpEF) combined with paroxysmal atrial fibrillation (PAF).Methods Two-hundred patients with HFpEF combined with PAF in Anhui No.2 Provincial People's Hospital from January 2023 to April 2023 were selected, and the patients were divided into the experimental group and the control group with 100 cases each by random number table method.Patients in the control group were treated with conventional drugs, and those in the experimental group were treated with conventional drugs combined with dapagliflozin.The monthly occurrence of atrial fibrillation and the longest duration of each atrial fibrillation, plasma N-terminal B-type natriuretic peptide precursor (NT-proBNP), interleukin-6(IL-6), left ventricular mass fraction (LVMI), left atrial volume index (LAVI), 24-hour average ventricular rate, and QTc interval before treatment and 3, 6 and 9 months after treatment, as well as adverse reactions during treatment, and re-hospitalization for heart failure after 9 months of treatment were observed.Results After 3, 6, and 9 months of treatment, the monthly occurrence of atrial fibrillation, the longest duration of each atrial fibrillation, NT-proBNP, IL-6, LVMI, LAVI, 24-hour mean ventricular rate, and QTc interval were significantly improved in both the control and experimental groups, and the degree of improvement increased with the prolongation of treatment time.At the same time, the improvement in the experimental group was significantly higher than that in the control group (all P < 0.05).After 9 months of treatment, the re-admission rate of heart failure in the experimental group was lower than that in the control group (38% vs 25%, χ²=3.916, P=0.048).During the treatment period, there was no statistically significant difference in the incidence of adverse reactions between the two groups (9% vs 7%, χ²=0.270, P=0.603).Conclusion Dapagliflozin can improve cardiac function, alleviate atrial and ventricular remodeling, improve long-term prognosis and has good safety in HFpEF patients with PAF.
- dapagliflozin /
- heart failure with preserved ejection fraction /
- paroxysmal atrial fibrillation /
- cardiac function

HTML全文

表 1 对照组与试验组基线资料比较

Table 1. Baseline data 例(%), X±S

指标	对照组 (100例)	试验组 (100例)	P
男/女/例	56/44	52/48	0.430
年龄/岁	59.01±6.10	57.45±9.60	0.269
BMI/(kg/m²)	24.92±3.14	25.94±3.24	0.056
左心房内径/mm	47.02±8.53	47.73±9.48	0.579
基础疾病
糖尿病	8(8.00)	9(9.00)	0.800
血脂异常	22(22.00)	24(24.00)	0.738
高血压	18(18.00)	20(20.00)	0.719
抗凝药物使用
华法林	5(5.00)	6(6.00)	0.757
利伐沙班	14(14.00)	13(13.00)	0.837
达比加群酯	10(10.00)	11(11.00)	0.818

下载: 导出CSV

表 2 对照组与试验组房颤发作情况比较

Table 2. Atrial fibrillation data X±S

指标	对照组(100例)	试验组(100例)
房颤每月发作/次
治疗前	9.67±1.12	9.86±1.15
治疗3个月	7.43±0.76¹⁾	5.95±0.62¹⁾⁴⁾
治疗6个月	5.64±0.59¹⁾²⁾	2.28±0.26¹⁾²⁾⁴⁾
治疗9个月	2.54±0.28¹⁾²⁾³⁾	0.85±0.07^1)2)3)4)
每次房颤最长持续时间/(h/次)
治疗前	2.54±0.28	2.56±0.30
治疗3个月	2.29±0.25¹⁾	2.11±0.23¹⁾⁴⁾
治疗6个月	1.75±0.19¹⁾²⁾	1.01±0.13¹⁾²⁾⁴⁾
治疗9个月	1.37±0.15¹⁾²⁾³⁾	0.68±0.08^1)2)3)4)
与同组治疗前比较，¹⁾P < 0.05；与同组治疗3个月比较，²⁾P < 0.05；与同组治疗6个月比较，³⁾P < 0.05；与对照组同期比较，⁴⁾P < 0.05。

下载: 导出CSV

表 3 对照组与试验组NT-proBNP和IL-6水平比较

Table 3. NT-proBNP and IL-6 levels pg/mL, X±S

指标	对照组(100例)	试验组(100例)
NT-proBNP
治疗前	1 724.88±310.91	1 640.49±389.04
治疗3个月	1 234.33±280.40¹⁾	1 033.08±226.60¹⁾⁴⁾
治疗6个月	935.50±289.54¹⁾²⁾	880.93±262.17¹⁾²⁾⁴⁾
治疗9个月	648.10±299.70¹⁾²⁾³⁾	503.97±246.57^1)2)3)4)
IL-6
治疗前	24.92±3.14	25.94±3.24
治疗3个月	18.56±2.32¹⁾	17.60±2.14¹⁾⁴⁾
治疗6个月	14.52±1.76¹⁾²⁾	10.02±1.40¹⁾²⁾⁴⁾
治疗9个月	12.60±1.57¹⁾²⁾³⁾	6.24±0.74^1)2)3)4)
与同组治疗前比较，¹⁾P < 0.05；与同组治疗3个月比较，²⁾P < 0.05；与同组治疗6个月比较，³⁾P < 0.05；与对照组同期比较，⁴⁾P < 0.05。

下载: 导出CSV

表 4 对照组与试验组LVMI和LAVI水平比较

Table 4. LVMI and LAVI levels X±S

指标	对照组(100例)	试验组(100例)
LVMI/(g/m²)
治疗前	99.47±10.10	101.870±9.50
治疗3个月	100.10±9.57	93.99±10.12¹⁾⁴⁾
治疗6个月	95.94±9.54¹⁾²⁾	91.51±10.11¹⁾²⁾⁴⁾
治疗9个月	93.51±9.55¹⁾²⁾³⁾	90.01±10.10^1)2)3)4)
LAVI/(mL/m²)
治疗前	50.06±4.12	50.07±5.03
治疗3个月	44.06±4.20¹⁾	39.09±4.09¹⁾⁴⁾
治疗6个月	37.06±4.27¹⁾²⁾	34.06±5.07¹⁾²⁾⁴⁾
治疗9个月	32.00±4.37¹⁾²⁾³⁾	23.01±5.17^1)2)3)4)
与同组治疗前比较，¹⁾P < 0.05；与同组治疗3个月比较，²⁾P < 0.05；与同组治疗6个月比较，³⁾P < 0.05；与对照组同期比较，⁴⁾P < 0.05。

下载: 导出CSV

表 5 对照组与试验组24 h平均心室率和QTc间期水平比较

Table 5. 24-hour average ventricular rate and QTc interval X±S

指标	对照组(100例)	试验组(100例)
24 h平均心室率/(次/min)
治疗前	89.83±10.85	91.54.±10.53
治疗3个月	86.98±11.21¹⁾	80.57±10.82¹⁾⁴⁾
治疗6个月	80.62±11.06¹⁾²⁾	77.98±10.85¹⁾²⁾⁴⁾
治疗9个月	71.92±10.85¹⁾²⁾³⁾	67.80±11.10^1)2)3)4)
QTc间期/ms
治疗前	540.56±56.94	545.83±56.97
治疗3个月	512.63±55.08¹⁾	482.82±50.26¹⁾⁴⁾
治疗6个月	488.25±52.06¹⁾²⁾	451.64±48.19¹⁾²⁾⁴⁾
治疗9个月	462.06±49.11¹⁾²⁾³⁾	434.20±46.39^1)2)3)4)
与同组治疗前比较，¹⁾P < 0.05；与同组治疗3个月比较，²⁾P < 0.05；与同组治疗6个月比较，³⁾P < 0.05；与对照组同期比较，⁴⁾P < 0.05。

下载: 导出CSV

表 6 对照组与试验组不良反应比较

Table 6. Adverse reactions 例(%)

项目	对照组 (100例)	试验组 (100例)	χ²	P
低血糖	1(1.00)	1(1.00)
尿路感染	2(2.00)	0
低血压	2(2.00)	2(2.00)
肝功能异常	2(2.00)	2(2.00)
肾功能异常	2(2.00)	2(2.00)
合计	9(9.00)	7(7.00)	0.270	0.603

下载: 导出CSV

参考文献(25)

[1]	张班, 刘晓刚, 胡立群. 射血分数保留的心力衰竭研究新进展[J]. 临床心血管病杂志, 2022, 38(4): 271-275. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.04.004
[2]	Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2022, 387(12): 1089-1098. doi: 10.1056/NEJMoa2206286
[3]	Reddy YNV, Borlaug BA, Gersh BJ. Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction[J]. Circulation, 2022, 146(4): 339-357. doi: 10.1161/CIRCULATIONAHA.122.057444
[4]	Diwan A, McCulloch M, Lawrie GM, et al. Doppler estimation of left ventricular filling pressures in patients with mitral valve disease[J]. Circulation, 2005, 111(24): 3281-3289. doi: 10.1161/CIRCULATIONAHA.104.508812
[5]	Little WC. Diastolic dysfunction beyond distensibility: adverse effects of ventricular dilatation[J]. Circulation, 2005, 112(19): 2888-2890. doi: 10.1161/CIRCULATIONAHA.105.578161
[6]	Rosenberg MA, Gottdiener JS, Heckbert SR, et al. Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study[J]. Eur Heart J, 2012, 33(7): 904-912. doi: 10.1093/eurheartj/ehr378
[7]	Sartipy U, Dahlström U, Fu M, et al. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction[J]. JACC Heart Fail, 2017, 5(8): 565-574. doi: 10.1016/j.jchf.2017.05.001
[8]	Bode D, Semmler L, Wakula P, et al. Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF[J]. Cardiovasc Diabetol, 2021, 20(1): 7. doi: 10.1186/s12933-020-01208-z
[9]	中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202406002.htm
[10]	中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6): 572-618. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYX202310002.htm
[11]	李中根, 李凌, 李黎, 等. 心外膜脂肪厚度与射血分数保留性心衰风险的相关性[J]. 临床心血管病杂志, 2022, 38(5): 393-399. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.05.012
[12]	Ţica O, Khamboo W, Kotecha D. Breaking the cycle of heart failure with preserved ejection fraction and atrial fibrillation[J]. Card Fail Rev, 2022, 8: e32. doi: 10.15420/cfr.2022.03
[13]	Jasic-Szpak E, Marwick TH, Donal E, et al. Prediction of AF in HeartFailure with preserved ejection fraction: incremental value of left atrial strain[J]. JACC Cardiovasc Imaging, 2021, 14(1): 131-144. doi: 10.1016/j.jcmg.2020.07.040
[14]	Kotecha D, Lam CS, van Veldhuisen DJ, et al. Heart failure with preserved EjectionFraction andAtrial fibrillation: vicious twins[J]. J Am Coll Cardiol, 2016, 68(20): 2217-2228. doi: 10.1016/j.jacc.2016.08.048
[15]	Chrysant SG, Chrysant GS. Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors[J]. Expert Rev Cardiovasc Ther, 2022, 20(3): 223-232. doi: 10.1080/14779072.2022.2057949
[16]	Pabel S, Hamdani N, Singh J, et al. Potential mechanisms of SGLT2 inhibitors for the treatment of heart failure with preserved ejection fraction[J]. Front Physiol, 2021, 12: 752370. doi: 10.3389/fphys.2021.752370
[17]	Gao J, Xue G, Zhan G, et al. Benefits of SGLT2 inhibitors in arrhythmias[J]. Front Cardiovasc Med, 2022, 9: 1011429. doi: 10.3389/fcvm.2022.1011429
[18]	Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(18): e895-e1032.
[19]	Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J]. J Am Coll Cardiol, 2013, 62(4): 263-271. doi: 10.1016/j.jacc.2013.02.092
[20]	Zhang N, Feng B, Ma X, et al. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction[J]. Cardiovasc Diabetol, 2019, 18(1): 107. doi: 10.1186/s12933-019-0914-1
[21]	黄学斌, 任小鹏, 解园星, 等. 慢性心力衰竭患者合并心房颤动的危险因素分析[J]. 中国循环杂志, 2015, 30(9): 863-866. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH201509012.htm
[22]	Bhat A, Chen HHL, Khanna S, et al. Clinical and cardiac structural predictors of atrial fibrillation persistence[J]. Eur J Clin Invest, 2021, 51(3): e13395.
[23]	Westergaard LM, Alhakak A, Rørth R, et al. Ventricular rate in atrial fibrillation and the risk of heart failure and death[J]. Europace, 2023, 25(5): euad088. doi: 10.1093/europace/euad088
[24]	李芳, 陈开, 沈启明. HFpEF患者血浆脑钠肽与超声心动图及心电图的相关性分析[J]. 中国循证心血管医学杂志, 2022, 14(9): 1111-1114. https://www.cnki.com.cn/Article/CJFDTOTAL-PZXX202209021.htm
[25]	王要鑫, 刘洁云, 秦雷, 等. 达格列净在非糖尿病老年患者急性ST段抬高型心肌梗死PPCI术后的近期疗效观察[J]. 临床心血管病杂志, 2023, 39(2): 126-129. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2023.02.010